NewLink Genetics receives contract option from BARDA to develop Ebola vaccine
The Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services (HHS) has awarded a $21.6m contract option to NewLink Genetics.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Contracts | Department of Health | Ebola | Ebola Vaccine | Genetics | Health | Pharmaceuticals | Vaccines